Fig. 1 · Structure

Documents & Downloads

BAM 7

Cat. No. A12907 CAS 331244-89-4

Bax activator

BAM 7 binds the BAX trigger site with an EC50 ~ 3.3 μM as measured in a competitive FP assay using FITC-BIM SAHB and BAX.

In Stock

Publications for BAM 7

1 publication citing this product

  1. Takino JI, .et al. , Sci Rep, 2019, Nov 13;9(1):16717 PMID: 31723205

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BAM7 is a small-molecule BAX activator characterized by competitive binding and NMR mapping near the N-terminal α1/α6 trigger site. The original study reported competition IC50 values of 3.31 μM for BAM7 and 4.41 μM after resynthesis. BAM7 also produced BAX-dependent release from model liposomes; BAX K21E and the inactive analog ANA-BAM16 served as negative controls. The competition IC50 is an assay endpoint, not a cellular treatment dose or a binding KD. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Bax EC50 3.3 μM

Cellular Effect

Cell Line Activity Value Description Reference
Huh-7 EC50 8.2 μM Activation of Bax in human HuH7 cells assessed as inhibition of mitochondrial accumulation of fluorescent probe Mitotracker Red after 12 to 72 hrs by spectrophotometric analysis [PMID: 25668341]
MEF EC50 > 50 μM Induction of apoptosis in Bax-deficient MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]
MEF EC50 > 50 μM Induction of apoptosis in Bax/Bak-deficient MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]
MEF EC50 3.2 μM Induction of apoptosis in Bcl2-deficient MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]
MEF EC50 3.5 μM Induction of apoptosis in Bad-deficient MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]
MEF EC50 4 μM Induction of apoptosis in Bid-deficient MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]
MEF EC50 6 μM Induction of apoptosis in Bak-deficient MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]
MEF EC50 7.7 μM Induction of apoptosis in wild-type MEF assessed as appearance of fragmented nuclei and cell membrane blebbing after 24 hrs by DAPI staining [PMID: 25668341]

BAM 7 Research Summary

This section summarizes 4 in vitro studies of BAM 7 from 2 published references. In vitro models include purified BAX or BAX K21E with ANTS/DPX-loaded liposomes.

BAM 7 In Vitro Studies

BAM7 decreased 24 h viability in Bak−/− mouse embryo fibroblasts that retain BAX over a 3.75–15 μM treatment series. BAX-deficient cells were resistant, and wild-type BAX reconstitution restored sensitivity while the K21E mutant did not. These genetic comparisons support BAX dependence in the tested MEF context. [1]

BAM7 responses also depended on cellular context. In TERT-immortalized HUVECs, 20 μM BAM7 decreased the viability signal and increased apoptosis in mock cells, whereas RasGRP2-overexpressing cells were protected. The study therefore supports BAM7 as a probe of BAX-associated apoptosis while showing that a protective signaling background can limit its cellular effect. [2]

BAX binding and trigger-site mapping

Biochemical assay · Recombinant full-length human BAX; FITC–BIM SAHB competition and 15N-BAX NMR [1]

BAM7 displaced FITC–BIM SAHB from BAX. Resynthesized BAM7 retained comparable competition potency. NMR perturbations were concentrated near the α1/α6 trigger-site region; the docked pose is a structural model, not a solved ligand-bound structure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Displacement of FITC–BIM SAHB from BAXIC50 3.31 μM; 95% CI: 2.66–4.12 μM[1]
Displacement by resynthesized BAM7IC50 4.41 μM; 95% CI: 3.60–5.55 μM[1]
BAX chemical-shift mappingQualitative localization Perturbed residues concentrated in the α1/α6 trigger-site region[1]

Literature-Reported Treatment Conditions

Treatment concentration
Serial BAM7 dilution; competition assay used 50 nM FITC–BIM SAHB and 500 nM BAX. NMR titration up to a 1:1 BAX:BAM7 ratio.
Exposure duration
Competition fluorescence polarization read at 20 min.
Method
Competitive fluorescence polarization and 1H–15N HSQC NMR
Reported limits
Assay vehicle not recovered from the cited binding methods; no KD is assigned from competition IC50.
Methods and source locations

Compound reported in the paper: BAM7; Compound label in the paper: BAM7 (compound 1)

Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.

Figure 1c,d; Figure 2a–c; Results/Discovery and Structural analysis; Methods/BAM7 characterization; SI/Fluorescence polarization binding assays and NMR samples

Displacement of FITC–BIM SAHB from BAX: Competitive fluorescence polarization; Figure 1c printed fit annotation — Figure 1c (printed annotation) and caption

Displacement by resynthesized BAM7: Competitive fluorescence polarization; mean and s.d. for experiments performed in at least triplicate — Figure 1c (printed annotation) and caption

BAX chemical-shift mapping: 15N-BAX titration; calculated chemical-shift significance threshold >0.009 p.p.m.; no affinity value extracted — Figure 2a and caption; Results/Structural analysis

BAX-dependent liposomal membrane permeabilization

Biochemical assay · Purified BAX or BAX K21E with ANTS/DPX-loaded liposomes [1]

BAM7 promoted BAX-dependent membrane permeabilization. BAM7 alone, BAX alone, BAX K21E with BAM7, and BAX with inactive analog ANA-BAM16 did not induce release in this assay. This is an isolated membrane system, not an animal experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Liposomal content releaseQualitative dose response Dose-responsive release with BAM7 plus BAX; no effect with either alone or with the K21E/ANA-BAM16 negative-control combinations.[1]

Literature-Reported Treatment Conditions

Treatment concentration
400 nM BAX; Figure 3b BAX:BAM7 ratios 1:1, 1:2, 1:4, 1:6, 1:8, 1:10 and 1:20.
Exposure duration
90 min endpoint; assay monitored at 30 °C.
Method
ANTS/DPX dequenching normalized to maximal release induced by tBID plus BAX.
Reported limits
Assay vehicle not specified in the targeted SI liposomal-release method. No absolute release percentages inferred from bars.
Methods and source locations

Compound reported in the paper: BAM7; Compound label in the paper: BAM7 (compound 1)

Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.

Figure 3b and caption; Results/Functional activation; SI/Liposomal release assay

Liposomal content release: ANTS/DPX liposomal release; Figure 3 caption reports mean and s.d. for experiments performed in at least triplicate. BIM SAHB positive comparator at BAX:peptide 1:2. — Figure 3b and caption; SI/Liposomal release assay

Genetic controls for BAM7-associated loss of MEF viability

Cell-based study · Bak−/−, Bax−/− and Bax−/−Bak−/− mouse embryo fibroblasts; double-knockout MEFs reconstituted with wild-type BAX or BAX K21E [1]

BAM7 reduced viability in Bak−/− MEFs that retain BAX, while Bax−/− and double-knockout cells were resistant under the tested conditions. Wild-type BAX reconstitution restored sensitivity, whereas K21E reconstitution did not. ANA-BAM16 lacked the BAM7-specific pattern.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability across BAX/BAK genotypes and BAX reconstitutionQualitative response BAX-dependent loss of viability; resistance in BAX-deficient or BAX K21E-reconstituted cells.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 3.75, 5.00, 7.50, 10.00 and 15.00 μM BAM7; matched ANA-BAM16 dose series.
Exposure duration
24 h
Method
CellTiter-Glo luminescent viability assay, normalized to vehicle-treated controls.
Vehicle
0.15% (v/v) DMSO
Reported limits
No cellular IC50 adopted; results are restricted to these engineered MEF models.
Methods and source locations

Compound reported in the paper: BAM7; Compound label in the paper: BAM7 (compound 1)

Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.

Figure 3c–e and caption; Results/cellular BAX dependence; Methods/Cell viability assay

Cell viability across BAX/BAK genotypes and BAX reconstitution: CellTiter-Glo at 24 h; mean and s.d. for experiments performed in at least triplicate. ANA-BAM16 comparator. — Figure 3c–e and caption; Methods/Cell viability assay

RasGRP2 expression limits the endothelial response to BAM7

Cell-based study · TERT-immortalized HUVECs: mock (M) versus RasGRP2-stable-overexpression (R) cells [2]

At 20 μM, BAM7 reduced the viability signal and increased NucView-positive apoptosis in mock cells, but not in RasGRP2-overexpressing cells. Values are relative to the 0 h viability signal, not to each time-matched untreated control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mock-cell viability at 24 h; 0 h = 100%Mean ± SD, n=3 Without BAM7: 127.8% ± 1.9%; with BAM7: 81.5% ± 3.2%; P < 0.01[2]
Mock-cell viability at 48 h; 0 h = 100%Mean ± SD, n=3 Without BAM7: 172.6% ± 2.0%; with BAM7: 65.2% ± 4.1%; P < 0.01[2]
RasGRP2-overexpressing-cell viability at 24 h; 0 h = 100%Mean ± SD, n=3 Without BAM7: 128.3% ± 2.7%; with BAM7: 129.5% ± 1.4%[2]
RasGRP2-overexpressing-cell viability at 48 h; 0 h = 100%Mean ± SD, n=3 Without BAM7: 174.6% ± 3.3%; with BAM7: 172.3% ± 2.1%[2]
NucView-positive apoptosis at 24 hQualitative comparison BAM7 increased apoptosis in mock cells but not RasGRP2-overexpressing cells.[2]

Literature-Reported Treatment Conditions

Treatment concentration
20 μM BAM7
Exposure duration
24 h and 48 h for viability; 24 h for NucView apoptosis.
Method
Cell Counting Kit-8 viability assay and NucView 488 apoptosis imaging.
Reported limits
Vehicle is not specified in the retrieved Methods. Figure caption n=3 is retained; Methods describe duplicate experiments repeated at least two or three times without defining independent biological n for each plotted point.
Methods and source locations

Compound reported in the paper: BAM7; Compound label in the paper: BAM7

Research findings for the reported BAM7 material and model; no salt conversion or commercial-lot potency certification.

Figure 1a,c,d; Results/RasGRP2 inhibits apoptosis; Methods/Reagents, Cell cultures, Cell viability, Measurement of apoptosis, Statistical analysis

Mock-cell viability at 24 h; 0 h = 100%: Cell Counting Kit-8; exact numbers from Results, not the curve — Results first paragraph; Figure 1a and caption

Mock-cell viability at 48 h; 0 h = 100%: Cell Counting Kit-8 — Results first paragraph; Figure 1a and caption

RasGRP2-overexpressing-cell viability at 24 h; 0 h = 100%: Cell Counting Kit-8; no significant reduction reported — Results first paragraph; Figure 1a and caption

RasGRP2-overexpressing-cell viability at 48 h; 0 h = 100%: Cell Counting Kit-8; no significant reduction reported — Results first paragraph; Figure 1a and caption

NucView-positive apoptosis at 24 h: NucView 488 detects caspase-3 activation; ratio normalized to mock-cell control; mean ± SD (n=3). No exact bar heights extracted. — Figure 1c,d and caption; Results second paragraph; Methods/Measurement of apoptosis

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 331244-89-4
Applications Bax activator
Formula C21H19N5O2S
Molecular Weight 405.47
SMILES
CCOC1=CC=CC=C1N/N=C/2\C(=NN(C2=O)C3=NC(=CS3)C4=CC=CC=C4)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 2 mg/mL (4.93 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

BAM 7 Research References

  1. [1] Gavathiotis E, Reyna DE, Bellairs JA, et al. Direct and selective small-molecule activation of proapoptotic BAX Nature chemical biology (2012). PMID: 22634637 DOI: 10.1038/nchembio.995 Source material
  2. [2] Takino JI, Sato T, Nagamine K, et al. The inhibition of Bax activation-induced apoptosis by RasGRP2 via R-Ras-PI3K-Akt signaling pathway in the endothelial cells Scientific reports (2019). PMID: 31723205 DOI: 10.1038/s41598-019-53419-4 Source material

Publications

1 publication citing this product

  1. Takino JI, .et al. , Sci Rep, 2019, Nov 13;9(1):16717 PMID: 31723205

Added to your cart

View Cart Checkout
Loading...